Exchange Ranking
Top Exchanges
24h Volume Ranking
Popularity Ranking
Exchange BTC Balance
Proof of Reserves
Decentralized Exchanges
Funding Rate
Funding Heatmap
Liquidation Data
Max Pain
Long/Short Ratio
Whale L/S Ratio
Binance/Okex/Huobi L/S
Bitfinex Margin L/S
ETF Tracker
Solana ETF
XRP ETF
Hong Kong ETF
Bitcoin Treasuries
Crypto Reversal
Ethereum Reserves
HyperLiquid Wallet Analysis
Hyperliquid Whale Watch
Large Transactions
On-chain Movement
Bitcoin ROI
Stablecoin Market Cap
Options Analysis
News
Articles
Economic Calendar
Features
Wallet
Contract Calculator
Security
Collections
Watchlist
FollowingCore Points
Ultragenyx Pharmaceuticals (RARE) shares plunged 45% in after-hours trading after a phase 3 clinical trial for the treatment of Angelman syndrome failed. The experimental therapy failed to achieve its primary goal and key secondary indicators, and the researchers observed no significant improvement between the medication group and the placebo group. The negative result raised serious concerns about the company's ongoing Aurora trial. The biopharmaceutical company plans to reduce operating costs while focusing on its commercial product portfolio, including newly approved Genglycos.
Impact on the ongoing Aurora trial
The disappointing Aspire study results have created huge uncertainty for the Aurora trial. Aurora is another ongoing clinical study to evaluate the effectiveness of apazunersen in treating patients with Angelman syndrome with different genetic variants. According to William Blair analyst Sami Corwin, even successful completion of Aurora's main endpoint does not necessarily guarantee commercial success. Corwin explained that the eligible patient population is still too limited to support an economically viable marketed product.
Previously, the U.S. Food and Drug Administration (FDA) granted apazunersen a number of important regulatory designations, including "breakthrough therapy" and "orphan drug" qualifications. These endorsements stem from the positive performance of early clinical data, so the later disappointment is particularly surprising. Ultragenyx announced that it will conduct a thorough review of apazunersen's development project to determine the next step. The company also plans to implement cost-cutting measures and reassess its strategic priorities.
Company shifts to commercial products
Despite major setbacks, Ultragenyx emphasizes that its expanding portfolio of approved therapeutic products is the foundation for continued operations. The company just received FDA approval last month for Genglycos, the first gene therapy approved to treat type 1 glycogen storage disease, commonly known as Von Gilk's disease. In addition, the company expects UX111 to gain regulatory approval for the treatment of Sanfilippo syndrome and continues to expand the geographical coverage of existing therapies. CEO Emil Kakkis emphasized that the company remains committed to achieving profitability in 2027.
The baseline characteristics of participants in the Aspire study were similar to those in the earlier Phase 2 survey, making the comparison results particularly confusing and exacerbating investor concerns. Ultragenyx confirmed that after the failure of the apazunersen trial, the company will fully support commercial products and conduct a thorough re-evaluation of the research and development pipeline.
Get 3 free stock e-books
Through expert analysis, discover top performing stocks in the fields of artificial intelligence, cryptocurrency and technology.
- Top Ten AI Stocks-Leading AI Companies
- Top Ten Cryptocurrency Stocks-Blockchain Leaders
- Top Ten Technology Stocks-Technology Giants
Disclaimer:
All content published on this website, including hyperlinks, related applications, forums, blogs, and other media accounts, originates from third-party platforms and their users. CoinMarketInsight makes no representations or warranties of any kind regarding the website or its content. All blockchain-related data and materials are provided for informational and research purposes only and do not constitute financial, legal, or investment advice. Users and third parties are solely responsible for the content they publish. CoinMarketInsight shall not be liable for any losses arising from the use of this website. You should exercise caution and conduct your own independent research, review, analysis, and verification before making any decisions.
Hot Coins
More-
BTC
$1.57万亿$78099.99
0.59% -
WBTC
$101.23亿$78058.15
0.59% -
WBT
$63.17亿$66000.00
5.61% -
TBTC
$2.26亿$62871.90
2.63% -
PAXG
$19.25亿$4463.26
0.09% -
XAUT
$27.31亿$4457.09
0.02% -
ULTIMA
$2.44亿$2786.70
2.40% -
WBETH
$33.81亿$2714.08
0.94% -
METH
$16.94亿$2707.82
1.22% -
ETH
$2965.23亿$2457.03
0.88% -
YFI
$8290.13万$2322.00
13.21% -
LSETH
$3.07亿$2004.96
0.85% -
BETH
$3.65亿$1779.50
1.17% -
ZEC
$140.80亿$838.18
5.60% -
SPYX
$1.63亿$755.59
0.25% -
QQQX
$1.50亿$717.95
0.64% -
BNB
$924.92亿$694.44
0.85% -
METAX
$8636.74万$608.12
2.17% -
XMR
$89.57亿$478.36
2.01% -
UNHX
$4946.38万$426.90
1.57%
-
Today's News
-
Ultragenyx's share price plunged 45% after failing a phase III clinical trial for Angelman's syndr...Ultragenyx (RARE) shares plummet 45% after failing key drug trials2026-09-03
-
Ciena's third-quarter results exceeded expectations, with adjusted earnings per share increasing by...Ciena (CIEN) shares surged 7% on strong third-quarter results and raised forecasts2026-09-03
-
Eos Energy's energy storage partnership with Google sent its share price up 18.75%, but financial l...Eos Energy (EOSE) shares rebound 19% on announced partnership with Google2026-09-03
-
Broadcom's Q3 revenue exceeded expectations and raised its long-term AI forecast, but its share pri...AVGO shares fell 2% despite a 221% surge in AI revenue in the third quarter2026-09-03
-
Cryptocurrency price forecast on September 3: Cardano tested US$0.208 resistance, Ripple approached ...Today's Cryptocurrency Price Forecast (September 3): Cardano (ADA), XRP and Ethereum (ETH)2026-09-03
-
Nvidia's second-quarter revenue increased by 106% year-on-year, exceeding expectations. It is expec...NVDA shares now account for 8% of the S & P 500 's total market value2026-09-03
-
Primavera has launched negotiations on three oil blocks in the Orinoco heavy oil belt in Venezuela, ...Coinbase co-founder Primavera seeks Venezuelan oil fields2026-09-03
-
XRP fell 2.29% due to macro risk aversion, but positive signs of ETF inflows provided bottom support...Macro risks hit cryptocurrency sentiment, XRP fell 2.29%2026-09-03
-
XRP fell 2.29%, as macro uncertainty pressured the crypto market, but optimism about spot ETF inflow...Macro risks hit market sentiment, XRP fell 2.29%, ETFs expected to support prices2026-09-03
-
Activist hedge fund Elliott took a stake in Deutsche Telekom and urged it to abandon its planned mer...Elliott increases its position in Deutsche Telekom, urging the company to abandon its merger with T-2026-09-03
-
Bitcoin (BTC) hovers around US$77,000. Analysts have different views on the US$83,000 gap and US$74,...Analysts: Bitcoin could plummet to $50,000 if bulls fail to pass key test2026-09-03
-
After Binance Alpha was launched, the price of the PONS token soared to a record high of US$0.52, bu...Binance Alpha is launched, and the token reaches a new high!2026-09-03
-
Bitwise research analysts pointed out that XRP has attracted the most attention among approximately ...Bitwise: XRP attracts the most attention from wealth management companies2026-09-03
-
After XRP fell below the US$1.36 support level, the technical side weakened, and analysts predicted ...Key support levels for XRP have been broken: Where are the important thresholds?2026-09-03
-
Gray reports showed that Bitcoin's correlation with Nasdaq fell to about 33%, while its correlation...Bitcoin is decoupled from Nasdaq, correlation with gold rises-Gray report2026-09-03
-
Solana's price is about US$99. It has corrected short-term but rose 35% in two weeks. ETFs have net...Solana Spot ETF has net inflows for 11th consecutive days, with Bitwise leading the way with US$6.172026-09-03
-
XRP became the most watched cryptocurrency at the wealth management seminar. Institutions such as Go...Wealth management circles are increasingly interested in XRP2026-09-03
-
XRP consolidates around US$1.36, buyers stick to the support level, resistance level of US$1.39 cont...XRP backtested support level, and the funding rate remained neutral2026-09-03
-
The CFTC asked the court to dismiss the CME lawsuit, arguing that it lacked legal qualifications and...CFTC plans to dismiss Chicago Mercantile Exchange's lawsuit over Bitcoin perpetual futures2026-09-03
-
Binance Alpha added PONS and $FLORK on September 2, triggering violent fluctuations in the prices of...Pons and Flork soared after Binance Alpha launched2026-09-03
More News
-
![Ultragenyx (RARE) shares plummet 45% after failing key drug trials]()
Ultragenyx (RARE) shares plummet 45% after failing key drug trialsUltragenyx's share price plunged 45% after failing a phase III clinical trial for Angelman's syndrome, and the company...2026-09-03 -
![Ciena (CIEN) shares surged 7% on strong third-quarter results and raised forecasts]()
Ciena (CIEN) shares surged 7% on strong third-quarter results and raised forecastsCiena's third-quarter results exceeded expectations, with adjusted earnings per share increasing by 215% year-on-year. ...2026-09-03 -
![Eos Energy (EOSE) shares rebound 19% on announced partnership with Google]()
Eos Energy (EOSE) shares rebound 19% on announced partnership with GoogleEos Energy's energy storage partnership with Google sent its share price up 18.75%, but financial losses exceeded expec...2026-09-03 -
![AVGO shares fell 2% despite a 221% surge in AI revenue in the third quarter]()
AVGO shares fell 2% despite a 221% surge in AI revenue in the third quarterBroadcom's Q3 revenue exceeded expectations and raised its long-term AI forecast, but its share price fell due to Q4 gu...2026-09-03 -
![Today's Cryptocurrency Price Forecast (September 3): Cardano (ADA), XRP and Ethereum (ETH)]()
Today's Cryptocurrency Price Forecast (September 3): Cardano (ADA), XRP and Ethereum (ETH)Cryptocurrency price forecast on September 3: Cardano tested US$0.208 resistance, Ripple approached US$1.41, and Ethereu... -
![NVDA shares now account for 8% of the S & P 500 's total market value]()
NVDA shares now account for 8% of the S & P 500 's total market valueNvidia's second-quarter revenue increased by 106% year-on-year, exceeding expectations. It is expected that revenue wil...2026-09-03 -
![Coinbase co-founder Primavera seeks Venezuelan oil fields]()
Coinbase co-founder Primavera seeks Venezuelan oil fieldsPrimavera has launched negotiations on three oil blocks in the Orinoco heavy oil belt in Venezuela, a personal investmen...2026-09-03 -
![Macro risks hit cryptocurrency sentiment, XRP fell 2.29%]()
Macro risks hit cryptocurrency sentiment, XRP fell 2.29%XRP fell 2.29% due to macro risk aversion, but positive signs of ETF inflows provided bottom support. Traders focused on... -
![Macro risks hit market sentiment, XRP fell 2.29%, ETFs expected to support prices]()
Macro risks hit market sentiment, XRP fell 2.29%, ETFs expected to support pricesXRP fell 2.29%, as macro uncertainty pressured the crypto market, but optimism about spot ETF inflows provided bottom su...
